AP2781A - Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechansim, from the use of these porteins or from the inhibition thereof - Google Patents
Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechansim, from the use of these porteins or from the inhibition thereofInfo
- Publication number
- AP2781A AP2781A AP2009004857A AP2009004857A AP2781A AP 2781 A AP2781 A AP 2781A AP 2009004857 A AP2009004857 A AP 2009004857A AP 2009004857 A AP2009004857 A AP 2009004857A AP 2781 A AP2781 A AP 2781A
- Authority
- AP
- ARIPO
- Prior art keywords
- porteins
- mechansim
- inhibition
- therapeutic
- derived
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Genetics & Genomics (AREA)
- AIDS & HIV (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10051983A DE10051983A1 (de) | 2000-10-20 | 2000-10-20 | Inhibierung der pathogenen Wirkung oxidierter Proteine |
DE2001148624 DE10148624A1 (de) | 2001-10-02 | 2001-10-02 | Oxidierte Proteine - ihre biologische Wirkung, sowie therapeutische und diagnostische Maßnahmen, die sich aus dem Wirkmechanismus, dem Einsatz dieser Proteine oder deren Inhibierung ableiten |
PCT/EP2001/012129 WO2002032445A2 (de) | 2000-10-20 | 2001-10-19 | Hemmung der interaktion zwischen oxidierte proteine und cd36 oder dessen wirkmechanismus |
Publications (2)
Publication Number | Publication Date |
---|---|
AP2009004857A0 AP2009004857A0 (en) | 2009-06-30 |
AP2781A true AP2781A (en) | 2013-10-31 |
Family
ID=26007431
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AP2009004857A AP2781A (en) | 2000-10-20 | 2001-10-19 | Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechansim, from the use of these porteins or from the inhibition thereof |
APAP/P/2003/002795A AP2034A (en) | 2000-10-20 | 2001-10-19 | Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
APAP/P/2003/002795A AP2034A (en) | 2000-10-20 | 2001-10-19 | Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof. |
Country Status (14)
Country | Link |
---|---|
EP (2) | EP1994941A3 (xx) |
JP (1) | JP4881535B2 (xx) |
AP (2) | AP2781A (xx) |
AT (1) | ATE406908T1 (xx) |
AU (1) | AU2002215032A1 (xx) |
CA (1) | CA2453140C (xx) |
CY (1) | CY1110418T1 (xx) |
DE (1) | DE50114289D1 (xx) |
DK (1) | DK1328289T3 (xx) |
ES (1) | ES2307662T3 (xx) |
HK (1) | HK1057857A1 (xx) |
OA (1) | OA12431A (xx) |
PT (1) | PT1328289E (xx) |
WO (1) | WO2002032445A2 (xx) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2523357C (en) * | 2003-04-25 | 2015-07-14 | Hamburger Stiftung Zur Foerderung Von Wissenschaft Und Kultur | Treatment of hi-virus infections with oxidised blood proteins |
CA2622911C (en) | 2005-09-16 | 2016-12-06 | Cornell Research Foundation, Inc. | Methods for reducing cd36 expression |
JP2010235447A (ja) * | 2007-07-30 | 2010-10-21 | Igaku Seibutsugaku Kenkyusho:Kk | 炎症性サイトカインの抑制剤 |
DE102010043733A1 (de) | 2010-11-10 | 2012-05-10 | Oxprotect Gmbh | Unbeladene PEGylierte Liposomen zur Verwendung als Arzneimittel zur Prophylaxe und Therapie von hämorrhagischen und thrombo- embolischen Erkrankungen |
DE102011003944A1 (de) | 2011-02-10 | 2012-08-16 | Oxprotect Gmbh | Detektion und Entfernung von missgefalteten Proteinen/Peptiden |
DE102011003936A1 (de) | 2011-02-10 | 2012-08-16 | Oxprotect Gmbh | Verwendung von Proteinen/Peptiden, welche an GRP78 (BIP) binden, in Labormethoden zum Monitoring von Thrombozyten-Aggregationshemmern |
US10531655B2 (en) | 2011-12-02 | 2020-01-14 | The Regents Of The University Of California | Reperfusion protection solution and uses thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991004744A1 (en) * | 1989-10-06 | 1991-04-18 | The Beth Israel Hospital Association | Methods and apparatus for treating disease states using oxidized lipoproteins |
WO1991010684A1 (en) * | 1990-01-08 | 1991-07-25 | Schering Corporation | Oxidized variants of gm-csf |
WO1992001467A1 (en) * | 1990-07-18 | 1992-02-06 | The Beth Israel Hospital Association | Method for treating viral infections using oxidized lipoproteins |
US5192264A (en) * | 1989-10-06 | 1993-03-09 | The Beth Israel Hospital Association | Methods and apparatus for treating disease states using oxidized lipoproteins |
WO1997021443A1 (en) * | 1995-12-14 | 1997-06-19 | Mark Borisovich Balazovskiy | Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof |
WO1999049883A2 (en) * | 1998-03-28 | 1999-10-07 | The University Court Of The University Of Glasgow | Oxidized thymosin beta 4 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3819923A1 (de) * | 1988-06-11 | 1989-12-21 | Behringwerke Ag | Fibrin(ogen)derivate, verfahren zu ihrer herstellung und ihre verwendung |
JPH09504797A (ja) | 1993-11-08 | 1997-05-13 | ペプチド デリバリー システムズ プロプリエタリイ リミテッド | ラベルされた診断用組成物と,その使用方法 |
DE69738503T2 (de) | 1997-06-20 | 2009-02-26 | Leuven Research & Development V.Z.W. | Versuchsanordnungen, antikörper und standards für den nachweis von oxidierten und mda-modifizierten lipoproteinen geringer dichte |
AU1243500A (en) * | 1998-11-06 | 2000-05-29 | Emory University | Biomarkers for oxidative stress |
DE10045047A1 (de) * | 2000-09-12 | 2002-03-21 | Beate Kehrel | Arzneimittel enthaltend aktiviertes Antithrombin III |
-
2001
- 2001-10-19 AP AP2009004857A patent/AP2781A/xx active
- 2001-10-19 EP EP08012302A patent/EP1994941A3/de not_active Withdrawn
- 2001-10-19 AT AT01983562T patent/ATE406908T1/de active
- 2001-10-19 OA OA1200300119A patent/OA12431A/en unknown
- 2001-10-19 WO PCT/EP2001/012129 patent/WO2002032445A2/de active IP Right Grant
- 2001-10-19 EP EP01983562A patent/EP1328289B1/de not_active Expired - Lifetime
- 2001-10-19 DK DK01983562T patent/DK1328289T3/da active
- 2001-10-19 DE DE50114289T patent/DE50114289D1/de not_active Expired - Lifetime
- 2001-10-19 JP JP2002535683A patent/JP4881535B2/ja not_active Expired - Fee Related
- 2001-10-19 AP APAP/P/2003/002795A patent/AP2034A/en active
- 2001-10-19 CA CA2453140A patent/CA2453140C/en not_active Expired - Fee Related
- 2001-10-19 PT PT01983562T patent/PT1328289E/pt unknown
- 2001-10-19 AU AU2002215032A patent/AU2002215032A1/en not_active Abandoned
- 2001-10-19 ES ES01983562T patent/ES2307662T3/es not_active Expired - Lifetime
-
2004
- 2004-01-05 HK HK04100053.0A patent/HK1057857A1/xx not_active IP Right Cessation
-
2008
- 2008-11-19 CY CY20081101332T patent/CY1110418T1/el unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991004744A1 (en) * | 1989-10-06 | 1991-04-18 | The Beth Israel Hospital Association | Methods and apparatus for treating disease states using oxidized lipoproteins |
US5192264A (en) * | 1989-10-06 | 1993-03-09 | The Beth Israel Hospital Association | Methods and apparatus for treating disease states using oxidized lipoproteins |
WO1991010684A1 (en) * | 1990-01-08 | 1991-07-25 | Schering Corporation | Oxidized variants of gm-csf |
WO1992001467A1 (en) * | 1990-07-18 | 1992-02-06 | The Beth Israel Hospital Association | Method for treating viral infections using oxidized lipoproteins |
WO1997021443A1 (en) * | 1995-12-14 | 1997-06-19 | Mark Borisovich Balazovskiy | Cytokine and hemopoietic factor endogenous production enhancer and methods of use thereof |
WO1999049883A2 (en) * | 1998-03-28 | 1999-10-07 | The University Court Of The University Of Glasgow | Oxidized thymosin beta 4 |
Non-Patent Citations (1)
Title |
---|
DAWSON DAVID W ET AL: "CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells." JOURNAL OF CELL BIOLOGY, Bd. 138, Nr. 3, 1997, Seiten 707-717, XP002215771 ISSN: 0021-9525 * |
Also Published As
Publication number | Publication date |
---|---|
EP1328289B1 (de) | 2008-09-03 |
EP1994941A2 (de) | 2008-11-26 |
CY1110418T1 (el) | 2015-04-29 |
ATE406908T1 (de) | 2008-09-15 |
PT1328289E (pt) | 2008-12-10 |
OA12431A (en) | 2006-04-19 |
AP2034A (en) | 2009-08-28 |
DE50114289D1 (de) | 2008-10-16 |
WO2002032445A3 (de) | 2003-04-17 |
WO2002032445A2 (de) | 2002-04-25 |
HK1057857A1 (en) | 2004-04-23 |
AU2002215032A1 (en) | 2002-04-29 |
AP2003002795A0 (en) | 2003-06-30 |
CA2453140A1 (en) | 2002-04-25 |
EP1328289A2 (de) | 2003-07-23 |
JP2004511526A (ja) | 2004-04-15 |
AP2009004857A0 (en) | 2009-06-30 |
EP1994941A3 (de) | 2012-07-25 |
JP4881535B2 (ja) | 2012-02-22 |
DK1328289T3 (da) | 2008-12-15 |
ES2307662T3 (es) | 2008-12-01 |
CA2453140C (en) | 2016-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60233157D1 (de) | Zweikammer-herzschrittmacher-system zur diagnose und behebung von arrhythmien | |
DE50014699D1 (de) | Medizinisches Instrument zum Präparieren von Gewebe | |
ATE318590T1 (de) | Arzneimittelkombinationen (z.b. chlorpromazin und pentamidin) zur therapie von neoplastischen erkrankungen | |
WO2002040634A3 (en) | Expression miniarrays and uses thereof | |
AU2002243370A1 (en) | Body supported activity and condition monitor | |
AU2002216273A1 (en) | Proteins, genes and their use for diagnosis and treatment of kidney response | |
AU2002226690A1 (en) | Drugs for the diagnosis of tissue-reproductive activity or the treatment of proliferative diseases | |
IL143699A0 (en) | Use of polypeptides or nucleic acids for the diagnosis or treatment of skin disorders and wound healing and for the identification of pharmacologically active substances | |
NO20013507L (no) | Blandinger for behandling av inflammatoriske reaksjoner | |
AU2002303261A8 (en) | Gene brcc2 and diagnostic and therapeutic uses thereof | |
GB0019302D0 (en) | Biological materials and the use thereof for the treatment of disease | |
AP2781A (en) | Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechansim, from the use of these porteins or from the inhibition thereof | |
AU6425800A (en) | Agents for the diagnosis, prognosis and treatment of malignant diseases | |
MXPA03006776A (es) | Uso de inhibidores de interleucina-18 para el tratamiento y/o prevencion de enfermedad cardiaca. | |
EP1200133A4 (en) | HANDLING OF FABRIC OR ORGAN TYPE USING THE NOTCH WAY | |
ZA200203269B (en) | Nucleic acids of the human ABC1 gene and their therapeutic and diagnostic application. | |
AU4204700A (en) | Compounds and methods for the diagnosis and treatment of (b. microti) infection | |
AU2001233954A1 (en) | Proteins, genes and their use for diagnosis and treatment of schizophrenia | |
AU2001240820A1 (en) | Proteins, genes and their use for diagnosis and treatment of vascular dementia | |
AU2002322301A1 (en) | Methods for the diagnosis and treatment of cardiac tissue rejection | |
WO2000063348A3 (fr) | Composition pharmaceutique comprenant des cellules nkt activees par des pim, et son utilisation en therapie | |
AU5611701A (en) | Agent for the diagnosis and therapy of viral diseases | |
MXPA02002864A (es) | Secuencias de arn de auto- escision y su uso para el control de sintesis de proteinas. | |
AU2002222308A1 (en) | Proteins, genes and their use for diagnosis and treatment of vascular response | |
ZA200108398B (en) | Anti-HIV-1 vaccine comprising all or part of the HIV-1 Tat protein. |